Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An 8-Week Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men

NCT02443090 is registered in ClinicalTrials.gov with NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.) as lead sponsor.

NCT NCT02443090
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02443090 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An 8-Week Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Oral Fispemifene for the Treatment of Sexual Dysfunction in Hypogonadal Men
Lead sponsor
NexMed (U.S.A.), Inc. (subsidiary of Apricus Biosciences, Inc.)
Phase
Phase 2
Overall status
Unknown status
Start date
May 31, 2015
Completion date
April 30, 2016
Enrollment
160 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

erectile dysfunction, secondary hypogonadism, sexual dysfunction